Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Mayne Pharma Group ( (AU:MYX) ) has provided an announcement.
UBS Group AG and its related bodies corporate have increased their voting power in Mayne Pharma Group Limited from 5.78% to 7.15% as of June 20, 2025. This change in substantial holding indicates a strategic move by UBS, potentially impacting Mayne Pharma’s shareholder dynamics and influencing its market positioning.
The most recent analyst rating on (AU:MYX) stock is a Buy with a A$7.09 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
More about Mayne Pharma Group
Average Trading Volume: 935,971
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$408.7M
For a thorough assessment of MYX stock, go to TipRanks’ Stock Analysis page.